↑ 2.02.1Bambico, Francis Rodriguez; Gobbi, Gabriella (2008). "The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets". Expert Opinion on Therapeutic Targets12 (11): 1347–1366. doi:10.1517/14728222.12.11.1347. ISSN1472-8222. PMID18851692.
↑ 4.04.1Saito, Viviane M.; Wotjak, Carsten T.; Moreira, Fabrício A. (2010). "Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?". Rev Bras Psiquiatr32 (1): 57–514. doi:10.1590/S1516-44462010000500004. ISSN1516-4446. PMID20512266.
↑ 5.05.1Micale, Vincenzo; Di Marzo, Vincenzo; Sulcova, Alexandra; Wotjak, Carsten T.; Drago, Filippo (2013). "Endocannabinoid system and mood disorders: Priming a target for new therapies". Pharmacology & Therapeutics138 (1): 18–37. doi:10.1016/j.pharmthera.2012.12.002. ISSN0163-7258. PMID23261685.
↑"Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology". J. Pharmacol. Exp. Ther.298 (1): 7–14. 2001. PMID11408519.